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Drug resistance forms the basis of the failure of most solid
tumours to respond to chemotherapy (Curt et al., 1984;
Goldie & Coldman, 1984). Nevertheless, resistance is rela-
tively exceptional in the normal dividing cell population and
their continued sensitivity limits the administration of chemo-
therapeutic agents (Goldie & Coldman, 1984).
It has recently been shown that some anticancer agents
inhibit DNA synthesis in normal cells, but not in the resis-
tant neoplastic cells (Bagshawe et al., 1987). If this were so
then it might be feasible to temporarily arrest the division of
the normal cells and selectively introduce into neoplastic
cells, that are in the S-phase, nucleotide analogues which
possess either cell killing potential or are suitable for scinti-
graphy (Bagshawe, 1986).
5-iodo-2-deoxyuridine (IUdR) is a synthetic analogue
which competes with thymidine for phosphorylation and sub-
sequent incorporation into newly formed DNA (Prusoff,
1959; Sneider & Potter, 1969). Non-selective uptake of IUdR
into normal cells precludes its effective use as a systemic
agent (Kinsella et al., 1985). Hydroxyurea (HU) is a ribo-
nucleotide reductase inhibitor which arrests DNA synthesis
reversibly and synchronises cells at the G,/S interphase of the
cell cycle (Tubiana et al., 1975).
Experimental work conducted by our group (Bagshawe et
al., 1987) has shown that human choriocarcinoma xenografts
(CC3), which are resistant to HU, show enhanced uptake of
'25-I-IUdR relative to the normal tissue (40 times) after pre-
treating mice with HU. Employing various sequences of
methotrexate (MTX), 5-fluorouracil (5FU), HU and 125I_1
IUdR relative uptake is augmented by 120 times. Methotrex-
ate inhibits thymidine synthesis and 5FU increases the
uptake of IUdR possibly by a combination of delayed deha-
logenation (Prusoff, 1963) and reduction of the thymidine
pool (Tattersall & Harrap, 1973).
This study involved 26 patients with biopsy proven malig-
nant neoplasms (mean age 51.6 ± 13.8 years, M : F 16: 10).
Disease activity and distribution was ascertained by history,
physical examination, and a chest radiograph. Additional
investigations included an ultrasound scan of the abdomen or
the pelvis, computerised axial tomography and isotope bone
scanning. Informed verbal consent was given by each patient
prior to entry into the study which was approved by the
Charing Cross Hospital Ethical Sub-committee.
'31I-IUdR was prepared from 2-deoxyuridine (Sigma,
Poole, UK) and Na'31', IBS30 (Amersham, UK) by an estab-
lished method (Keough & Hofer, 1977) with only minor
modifications. Specific activities of the order of 6 mCi mg'
were obtained.
HU was administered orally in a dose of 2.0 g twice weekly
2-3 weeks prior to '31'-IUdR administration in order to
encourage the neoplastic cells to develop resistance to it. The
thyroid was blocked with potassium iodide, 120 mg three
times a day for 7 days starting 24 h before the radiolabelled
IUdR was given. Potassium perchlorate, 200 mg thrice daily
was commenced 12 h prior to '3'I-IUdR to reduce secretion
of '3'I into the stomach and continued for a total of 4 days.
5FU (200 mg m-2) was given intravenously as a bolus follow-
ed 30 min later by sequential intravenous injections of 5FU
(600mgm2) and HU (3.0gmm-2). Ten minutes later 5-15
mCi of '3'I-IUdR were administered intravenously over
10min.
Planar imaging was obtained 24 and 48 h after the admin-
istration of the '3'I-IUdR using an IGE Gemini gamma
camera. Overall, 35% of the documented lesions revealed
uptake (Table I). Of the 26 patients investigated, 13 (50%)
showed evidence of uptake by at least one disease site (Table
II). No significant bone marrow toxicity (WHO grade > 3)
followed this regimen as determined by a full blood count
performed 2-3 weeks following the treatment. Three out of
four previously documented brain lesions showed marked
uptake of radioactivity. No uptake was demonstrated at
previously unknown sites except for the patient with leiomyo-
sarcoma in which uptake was shown at a subcutaneous site.
In most patients there was a significant uptake by the spine
and the stomach. Uptake was also noted in the breasts in
three patients free from any breast pathology. There was no
obvious correlation between dose of radioactivity admin-
istered and positive definition of tumours and similar images
were obtained at 24 and 48 h after "1'I-labelled IUdR
administration.
This pilot study explores the uptake of "311-labelled IUdR
by neoplasms in vivo. Intra-abdominal deposits could have
been overshadowed by the relatively high radioactivity
retained in the spine and the stomach in many of the cases.
Cerebral lesions on the other hand were well detected prob-
ably due to lack of rapidly proliferating cells in adjacent
tissues.
Some lesions may have been missed simply because their
DNA synthesis was suppressed by HU along with that of the
host. Also, the pre-treatment with HU may have been inade-
quate to induce resistance to the drug by the tumour cells.
Variations in the identification of tumours at various sites, if
not merely determined by tumour size and vascularity (Bram-
mer et al., 1979), could be due to differences in cell kinetics.
It is possible that some tumour cells in vivo are protected
either by poor blood flow or by minimal dependence on
Table I Results of uptake of '3'I-IUdR by known active disease
sites
Site ofdisease Total Positive Negative
Liver 11 7 4
Lungs 9 3 6
Brain 4 3 1
Pelvis (soft tissue) 5 2 3
Bone 2 0 2
Abdominal lymph glands 3 0 3
Skin and subcutaneous 2 0 2
tissues
Peripheral lymph glands 4 0 4
Kidney 1 0 1
Spleen 2 0 2
Total 43 15 (34.9%) 28
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exogenous thymidine pathways from incorporating '1I-IUdR
and may even tend to arrest temporarily in response to the
5FU induced suppression of de novo thymidine formation.
Despite this low sensitivity, specificity appears to be high and
unlike other targeted isotope imaging techniques there is no
significant non-specific retention of radioactivity in blood,
liver or lungs.
This pilot study demonstrates that a significant proportion
of human tumours demonstrate detectable uptake of 131-
IUdR. Scheduling of drug administration was based on the
pre-clinical studies in animal xenografts although further
investigation should include biochemical and cell kinetic
analysis of tumours and normal cells for evidence of sen-
sitivity. Findings of this study warrant further detailed and
controlled studies to explore the relation between the
pharmacokinetics of drugs and tissue kinetics in vivo. Such
studies may provide the basis for manipulating the regulatory
balances that will determine the selective uptake of IUdR
into tumour cells. If this were achieved, it would have impli-
cations for the incorporation of radiolabelled IUdR with
therapeutic benefit.
Table II Results of scintigraphy in 26 patients with various
tumours
True False
Tumour type Total positive negative
Adenocarcinoma (GI) 6 5 1
Oat cell lung cancer 3 2 1
Testicular teratoma 3 0 3
Breast adenocarcinoma 3 1 2
Non-Hodgkin's lymphoma 2 0 2
Renal cell carcinoma 2 1 1
Choriocarcinoma 1 1 0
Ovarian adenocarcinoma 1 1 0
Leiomyosarcoma 1 1 0
High grade glioma 1 1 0
Sq. cell ca of cervix 1 0 1
Prostatic adenocarcinoma 1 0 1
Malignant melanoma 1 0 1
Total 26 13 (50%) 13
True positive indicates uptake ofradioactivity in at least one disease
siteperpatient. Falsenegativeindicatesnouptake atanysiteinapatient
with known disease site(s).
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